-
Zennova Pharmaceutical Group Secures RMB 100 Million in Series B Financing for Commercial Manufacturing and R&D
•
China-based Zennova Pharmaceutical Group has reportedly raised close to RMB 100 million (USD 13.9 million) in a Series B financing round, with Hengbao Investment Holdings being the sole participant. The funds raised will be directed towards the commercial manufacturing and market launch of Zennova’s products, as well as new product…
-
Ocumension Therapeutics’ OT-101-S Myopia Treatment Accepted for CDE Review
•
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) has announced that the Center for Drug Evaluation (CDE) has accepted the Phase III clinical filing for its in-house developed OT-101-S, a treatment aimed at delaying or arresting child myopia. This development marks a significant step forward in the advancement of this novel…
-
Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent
•
The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and enforceability of a core patent for Swiss pharmaceutical giant Novartis’s (NYSE: NVS) hypertension therapy, Entresto (sacubitril, valsartan), based on modified claims. The patent in question, No. ZL200680001733.0, titled “drug combination product of angiotensin II receptor…
-
Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices
•
Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter of 2023, reporting robust sales growth of 7.5% year-on-year (YOY) in constant currency terms, reaching USD 25.5 billion. The performance was driven by all business segments, with the pharmaceutical unit Janssen expanding by 3.8% YOY…
-
Sartorius Expands Global Footprint with New Cell Culture Facility in Puerto Rico
•
Germany-based laboratory services firm Sartorius has expanded its operations with the opening of a new cell culture facility in Puerto Rico, following an investment of USD 33 million. The 2,000 square meter site is designed to manufacture culture media used in the production of protein-based drugs, catering specifically to the…
-
Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026
•
The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar development center in Slovenia by 2026, with an investment of approximately USD 90 million. This new project complements an existing generics plant and a planned biologic drugs factory in the country, valued at over USD…
-
Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority
•
United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging the US government’s authority to negotiate the price of selected drugs for the 2026 period onwards through the elderly health insurance program, Medicare. The company argues that such a project would damage innovation and potentially…
-
GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate to Switzerland’s LimmaTech Biologics for further development and commercialization. This strategic move builds upon GSK’s acquisition of LimmaTech’s predecessor company, GlycoVaxyn, in 2015, which included the vaccine in its portfolio. Phase I/II Development and Multivalent…
-
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
•
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts’ consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in…
-
Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug
•
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval from the National Medical Products Administration (NMPA) for its anti-insomnia drug, Quviviq (daridorexant), co-developed with Swiss firm Idorsia Pharmaceuticals Ltd. The dual orexin receptor antagonist (DORA) is now cleared for testing in the treatment of…
-
Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese firm Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Under the terms of the agreement, Livzon will obtain all rights to Synergy Pharma’s HHT120 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. In…
-
Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services
•
China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with Japan-based Daiichi Sankyo (TYO: 4568). The collaboration aims to delve deeply into the fields of cardiovascular and cerebrovascular diseases, rheumatic bone surgery, and other areas. Additionally, the two companies will explore a patient-oriented, digitalization-driven healthcare…
-
Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy
•
A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib, and Australia-based Telix Pharmaceuticals’s (ASX: TLX) targeted radiation therapy, TLX250 (177Lu-DOTA-girentuximab), has enrolled its first participant. This open-label dose escalation and dose expansion trial is designed to evaluate the safety profile, dosing, and activity of…
-
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National Medical Products Administration (NMPA) has granted another indication approval for its medication Sirturo (bedaquiline). The product is now approved for the treatment of adolescents aged 12-18 years and weighing ≥30kg with multidrug-resistant pulmonary tuberculosis (MDR-TB),…
-
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I clinical study for its recombinant Group B meningococcal vaccine (Escherichia coli), marking a significant step in assessing the vaccine’s safety, tolerability, and preliminary immunogenicity. This product is the first of its kind to enter clinical…
-
Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China
•
The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s (SHA: 688321) Epidaza (chidamide) has been granted priority status for the treatment of treatment-naïve diffuse large B-cell lymphoma (DLBCL) patients with positive MYC and BCL2 expression when used in combination with R-CHOP (rituximab, cyclophosphamide, adriamycin,…
-
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
•
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib) and Tyvyt (sintilimab) has been granted Breakthrough Therapy Designation (BTD) in China for the treatment of patients with mismatch repair normal (pMMR) advanced endometrial cancer. These patients have previously failed at least one line of…
-
Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial for KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA). This in-house developed treatment has completed its first patient enrollment in China. Phase III Clinical Trial Design and ObjectivesThe…
-
Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology
•
Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has entered into a partnership with Shanghai-headquartered medical imaging company United Imaging Healthcare (UIH, SHA: 688271). The collaboration aims to harness the power of advanced medical intelligent technologies to enhance medical services. Integrating AI and Nuclear…
-
Novomics Partners with TopGene to Expand Genomic Testing Services in China
•
South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei TopGene Biotechnology Co., Ltd to extend its presence in the Chinese market. Under this collaboration, TopGene will facilitate access to Novomics’ genomic testing services, including diagnostic kits and genetic information consulting, specifically for Chinese gastric…
